Innovative Paths to Paediatric Care: A Multicenter Study on the Efficacy of Multi-Domain Technological and Robotic Rehabilitation.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 194
- 试验地点
- 6
- 主要终点
- Canadian Occupational Performance Measure (COPM)
研究概览
简要总结
The goal of this clinical trial is to demonstrate the efficacy of multi domain robotic and technological rehabilitation on everyday life and satisfaction in children with neuromotor conditions. The main questions it aims to answer are:
- Will we have significant changes using the COPM in children taking part in the sperimental group?
- The children who will undergo the multidomain treatment will also experience functional improvements in individual areas?
- Thy type of treatment will improve motivation, active participation and satisfaction in children?
Researcher will compare the multidomain treatment to standard care proposed by the included clinical centers: single domain rehabilitation with one innovative device. Both groups will undergo also conventional multidomain therapy.
This will be done to see if using a holistic approach, and including every need of the child in the rehabilitation plan, can lead to greater improvements in quality of life compared to the control group.
Participant will:
-
Be evaluated 3 times with clinical outcome measures
-
Take part in a rehabilitation program, at least 20 x 2hours sessions treatment, organized in:
-
4 weeks, 5 times per week
-
7 weeks, 3 times per week
详细描述
- The sample size was determined considering the primary outcome (the change in COPM): the superiority of robotic treatment compared to conventional treatment; a power of 80%; a number of groups equal to 2; a number of measurements equal to 3; and an effect size of 0.1. Based on these parameters, a sample size of 162 patients (81 per group) is obtained. Additionally, considering a dropout rate of 20%, a total sample size of 194 patients is required.
- For each recruited subject, a specific checklist (CRF) will be completed to collect the demographic, clinical, and technological data required by the study. All collected data will be pseudonymized (using a technique that modifies and masks personal and sensitive data to prevent it from being directly and easily attributed to an individual), in accordance with current privacy regulations. This will allow for regular monitoring of the study's progress, particularly regarding the number of subjects enrolled and recruited in the different phases, the evaluation tests conducted, adherence to the study, and the treatment protocols implemented.
- A high adherence to the study is anticipated, especially if the children involved receive treatment during the care period in rehabilitation facilities, in compliance with current regulations. To ensure the quality and consistency of the intervention, a careful assessment of adherence will be conducted. This assessment will be carried out by an independent team of clinical reviewers, who will regularly monitor treatment sessions. The reviewers will then implement targeted strategies to maintain and improve adherence, including periodic training sessions for the staff involved and timely feedback directed to the therapists in both study groups. A diary will also be maintained regarding the treatments performed by each patient to monitor adherence to the proposed treatment.
- Regarding the collection of data obtained from standardized clinical evaluations, each subject will be assigned a numeric ID code in accordance with current privacy regulations, allowing for the preservation and sharing of data in a completely anonymous form with other participating centers. The list linking the assigned code to each child's name will be kept by the principal investigator and stored in a locked cabinet. Only the principal investigator and other researchers involved in the project will have access to this information.
Similarly, information obtained during the rehabilitation phase from technological tools will be stored and shared with other participating centers in a completely anonymous manner, using the same numeric code previously defined. The data collected throughout the study, excluding the subject's name, will be recorded, processed, and stored for at least seven (7) years after the conclusion of the study, along with the assigned code, on password-protected hard drives stored in a physically secured location or within protected electronic archives (Research Electronic Data Capture (RedCap)), accessible only to the principal investigator and authorized researchers. After seven years, the data will be destroyed.
All collected information will not be processed or used for purposes other than those indicated in the study's objectives, nor for direct profit, and will not be communicated or transferred to unauthorized third parties.
Personal data will be collected and processed in accordance with the principle of data minimization and in compliance with all general principles outlined in Article 5 of the GDPR. Data, particularly personal and health-related data, will be processed only to the extent necessary in relation to the objectives of the trial, in accordance with EU Regulation 2016/679 (GDPR) and Legislative Decree No. 101 of August 10, 2018.
At the time of data collection, whether obtained from standardized clinical evaluations or from device reports, the Data Controllers will ensure that the collected data is pseudonymized by identifying the recruited subjects with codes or adopting other solutions compliant with point 5.4 of the Privacy Authority Provision No. 146/2019. The use of encryption techniques allows for the storage and processing of the data subject's information in a way that prevents identification by any external person. Only the Project Manager at each center and authorized personnel can link each code to the name of the participating subject.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 21 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of developmental disorder and/or disability, either congenital or acquired;
- •Age between 5 and 21 years at the time of recruitment;
- •Verbal and/or non-verbal reasoning abilities > 70 or > 5th percentile, as assessed by standardized tests such as Colored Progressive Matrices (CPM), WISC-IV or WISC-V, WPPSI-III or WPPSI-IV, Leiter-3, Griffiths III.
排除标准
- •Presence of severe comorbidities and/or behavioral/cognitive disorders that prevent adequate patient compliance with both conventional and robotic rehabilitation treatment (severe intellectual disability);
- •Uncontrolled epilepsy;
- •Presence of severe sensory deficits;
- •Patients who have undergone orthopedic functional surgery or rhizotomy and/or botulinum toxin treatment in the last 6 months;
- •Involvement of the peripheral nervous system
研究组 & 干预措施
Single domain treatment group
Participant will undergo a Single domain rehabilitation treatment using only one innovative technological or robotic device.This will also be associated with the conventional rehabilitation
干预措施: Single domain intervention (Device)
Multidomain treatment group
Participant will undergo a Multidomain rehabilitation treatment using the combination of two or more innovative technological and robotic devices.This will also be associated with the conventional rehabilitation
干预措施: Multidomain intervention (Other)
结局指标
主要结局
Canadian Occupational Performance Measure (COPM)
时间窗: baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2)
Assessment tool used in occupational therapy to evaluate an individual's performance and satisfaction in both daily and personal activities. The COPM focuses on activities that are meaningful to the assessed person, allowing them to identify areas where they wish to improve their abilities or participation. This tool helps therapists better understand their patients' needs and desires, enabling them to plan targeted therapeutic interventions to enhance their quality of life and overall well-being.
次要结局
- Melbourne Assessment-2 (MA2)(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- ABILHAND-Kids.(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- Six Minutes Walking Test (6MWT)(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- Gross Motor Function Measure-88 (GMFM-88).(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- NEPSY-II inibition and auditory attention subtest(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- VMI(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- BVN 12-18 language, reading and writing subtest(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- Leiter 3- Sustained attention subtest(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- BVSCO-3(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- Tower of London (ToL)(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- MT-3 tests(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- BVL 4-12(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- 3D Gait Analysis: Joint kinematics(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- HTA Questionnaires(Up to 7 weeks after the baseline (T1))
- 3D Gait Analysis: Kinetics - Ground Reaction Force(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- 3D Gait Analysis: Kinetics - Joint power(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- 3D Gait Analysis: Kinetics - Joint moments(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
- 3D Gait Analysis: Spatiotemporal parameters(baseline(T0), up to 7 weeks (T1) and 2 months after the end of the training (T2))
